Adam Walsh
Stock Analyst at Roth MKM
(3.27)
# 2,345
Out of 4,579 analysts
127
Total ratings
43.2%
Success rate
4.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Reiterated: Buy | $12 | $2.46 | +387.80% | 10 | Jul 24, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $5.76 | +247.22% | 6 | Jul 15, 2026 | |
| OSTX OS Therapies | Initiated Coverage: Buy | $7 | $1.53 | +357.52% | 1 | Jul 9, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $36 | $20.88 | +72.41% | 2 | Jun 17, 2026 | |
| INSM Insmed | Maintained: Buy | $212 | $104.73 | +102.43% | 21 | Jun 8, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $31.02 | +86.98% | 4 | May 13, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $70 → $82 | $26.89 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $253.42 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Maintained: Buy | $298 | $28.13 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Maintained: Hold | n/a | $91.12 | n/a | 8 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 | $7.05 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $25 | $1.59 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $135.56 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $0.527 | n/a | 3 | Nov 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $479.00 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $60.27 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $225.61 | $6.34 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $278.40 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $15.89 | n/a | 2 | May 20, 2015 |
Equillium
Jul 24, 2026
Reiterated: Buy
Price Target: $12
Current: $2.46
Upside: +387.80%
Arcturus Therapeutics Holdings
Jul 15, 2026
Reiterated: Buy
Price Target: $20
Current: $5.76
Upside: +247.22%
OS Therapies
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.53
Upside: +357.52%
BioAge Labs
Jun 17, 2026
Reiterated: Buy
Price Target: $36
Current: $20.88
Upside: +72.41%
Insmed
Jun 8, 2026
Maintained: Buy
Price Target: $212
Current: $104.73
Upside: +102.43%
vTv Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $58
Current: $31.02
Upside: +86.98%
Ultragenyx Pharmaceutical
May 18, 2020
Maintained: Buy
Price Target: $70 → $82
Current: $26.89
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $253.42
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Maintained: Buy
Price Target: $298
Current: $28.13
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Maintained: Hold
Price Target: n/a
Current: $91.12
Upside: n/a
Nov 12, 2019
Maintained: Buy
Price Target: $71
Current: $7.05
Upside: n/a
Jun 25, 2019
Maintained: Buy
Price Target: $36 → $25
Current: $1.59
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $135.56
Upside: n/a
Nov 5, 2018
Maintained: Buy
Price Target: $35
Current: $0.527
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $479.00
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $60.27
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $225.61
Current: $6.34
Upside: n/a
Jun 24, 2015
Maintained: Buy
Price Target: $160
Current: $278.40
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $15.89
Upside: n/a